Benzinga | Nov 24, 2021 08:06AM EST

Advaxis Issues Letter, Second Video Message To Stockholders Regarding Upcoming Special Meeting

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders:

Dear Fellow Advaxis Stockholders:

I am writing to provide you with additional information and resources regarding the Company's proposed merger with Biosight. We believe that the proposed Biosight transaction can generate significant value for Advaxis stockholders. The combined company will be better capitalized and well-positioned to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors. The closing of the transaction is contingent upon, among other things, the approval of Advaxis' stockholders at the Special Meeting initially held on November 16, 2021 and adjourned to December 7, 2021.

Please go to the Advaxis website to watch the video entitled "Message About Proxy Proposal 2" we prepared to provide you with some additional information about the Biosight transaction and proxy proposal 2 to help inform your voting decision.

In addition, two leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis & Co., have recommended that stockholders vote "FOR" all of the proposals at the special meeting. We strongly urge you to vote today in support of the merger and related proposals.

How to Vote

To vote, or if you have already voted and would like to change your vote, or if you have any questions or need assistance voting your shares, please call the firm assisting us with the solicitation of proxies:

Kingsdale Advisors

1-888-518-1560 (toll free)

contactus@kingsdaleadvisors.com

Thank you for attention to this matter.

Kenneth A. Berlin

President and Chief Executive Officer

and Interim Chief Financial Officer